$DHR

2 theses

bullish 100%neutral 0%bearish 0%

Avg return (3m)

—

Win rate (3m)

— (0 resolved)

1d 3d 1w 1m 3m 6m 1y

Past performance does not predict future results. Informational only, not investment advice.

Recent theses

Prices as of Sep 10, 4:30 PM ET

$DHRr/ValueInvestingIndustry/Sectorbullish

u/Sylentwolf8 · 35d ago3 prior · awaiting results

The Chinese State 5-Year Plan - Who will profit?

China's state-subsidized biomanufacturing expansion will require high-end precision equipment for monitoring, filtering, and validating output for export-grade biological products. Danaher's chromatography resins, membranes, and analytical instruments are regulatory standards that Chinese factories cannot replace without risking compliance failures, creating sustained demand tailwinds.

At post $204.76Now $200.53-2.1% since postedas of Sep 10, 4:30 PM ET

1d—

3d+2.3%

1w-1.1%

1m+1.4%

3m—

6m—

1y—

original post →

$DHRr/ValueInvestingIndustry/Sectorbullish

u/raytoei · 48d ago9 prior · awaiting results

Medical-Device Stocks Are in the Bargain Bin. 6 to Buy - Barron’s

Danaher's recent sell-off was overdone; the company beat earnings, raised full-year guidance to $8.53 per share, and demand for lab supplies and diagnostics remains intact as confirmed by competitor Thermo Fisher's results. At attractive valuations, the stock represents a buying opportunity.

At post $196.50Now $200.53+2.0% since postedas of Sep 10, 4:30 PM ET

original post →

End of results.